✨ Free AI Report
Salignostics: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Salignostics
Company Research

Salignostics: Business Overview, Financials & Competitive Analysis

Salignostics is an R&D company that focuses on the development of saliva-based rapid diagnostics tests, addressing a critical gap in non-invasive healthcare diagnostics. The company's first commercially successful pro...

Analyst-debate audio for Salignostics

AskCyborg analysts argue the bull and bear cases for Salignostics across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Solid

Cyborg Score thesis

Salignostics is poised to capture significant share in the $XX billion rapid diagnostics market by making non-invasive saliva...

Read the full analyst-debate transcript →
Industry In-Vitro Diagnostics
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 12, 2026
AI-Verified Research
30+ Page Report

Get the Latest Salignostics Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Salignostics Overview

Pro stress-test →

Salignostics is an R&D company that focuses on the development of saliva-based rapid diagnostics tests, addressing a critical gap in non-invasive healthcare diagnostics. The company's first commercially successful product is Salistick, a saliva-based pregnancy test, with more than 500,000 units sold and ordered after launch in Israel and the UK (early 2024). The platform enables faster, cheaper, and more accessible testing across multiple disease categories.

Strategic Profile

Pro stress-test →

Salignostics has assembled a team of experts in saliva research and tech and business development, with 15 years of experience in the field. The company has launched three innovative saliva-based diagnostic products: Salistick, SaliCov (COVID-19), and Salicomb (collection device), with Salistick now accessible in over 1,500 retail locations and recognized with a 2023 Time Magazine Best Invention award. The company plans to expand its portfolio to address streptococcus, STDs, and cardiac risk indicators.

Competitive Landscape

Pro stress-test →

Salignostics competes in rapid point-of-care diagnostics against established players like Abbott, Quidel, and newer entrants focused on non-invasive testing. Competitors include traditional pregnancy test manufacturers (urine-based), COVID-19 test providers, and emerging saliva diagnostic startups. Salignostics' differentiation rests on its proprietary saliva platform enabling faster, lower-cost, and non-invasive testing across multiple indications.

Industry Context

Salignostics operates in In-Vitro Diagnostics.

Key facts

Founded: Not publicly disclosed; leadership has 15+ years industry experience · Headquarters: Jerusalem, Israel · Employees: 10–50 · Revenue: Estimated $5M–$25M (private company; based on 500K+ Salistick units and early-stage commercialization)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Salignostics.

  • Salistick pregnancy test surpassed 500,000 units sold and is stocked in 1,500+ retail locations across Israel, UK, and Australia, validating market demand for non-invasive saliva diagnostics and establishing distribution channels for pipeline products.
  • Company holds proprietary lateral flow immunoassay platform that overcomes technical barriers preventing saliva-based testing, creating a defensible technology moat as it expands from pregnancy into COVID-19, Strep A, and sexually transmitted infections.
+1 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2024Featured in Forbes article highlighting Salistick's market expansion and pipeline for COVID-19, STI, and cardiac risk diagnostics
  • Early 2024Salistick launched commercially in Israel and UK; 500,000+ units sold and ordered within months
  • +1 moreTrack every material event for Salignostics as it happens. Explore monitoring →
Get alerted when Salignostics has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

BinaxNOWRapid point-of-care diagnostic tests (COVID-19, influenza, RSV)→SofiaRapid diagnostic assays and point-of-care testing platforms→ClearblueRapid home diagnostic tests including pregnancy and fertility→Standard rapid diagnosticsIn vitro diagnostics and point-of-care testing→

Compare Salignostics with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Salignostics operates in In-Vitro Diagnostics. See how the rest of the sector scores on the Cyborg framework.

Browse In-Vitro Diagnostics research →
NEW · MCP server

Ask your AI assistant about Salignostics

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Salignostics and its top competitor on Cyborg Score”
“What did Salignostics do this quarter?”
“Is Salignostics a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Salignostics do?+
Salignostics is an R&D company that focuses on the development of saliva-based rapid diagnostics tests, addressing a critical gap in non-invasive healthcare diagnostics. The company's first commercially successful pro...
What is Salignostics's Cyborg Score?+
Salignostics has a Cyborg Score of 7/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Salignostics's main competitors?+
Named competitors include BinaxNOW, Sofia, Clearblue, Standard rapid diagnostics. The full competitive landscape is in the AskCyborg report.
How can I get the full Salignostics research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Salignostics research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Salignostics over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More In-Vitro Diagnostics research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7DiaSorin S.p.A.7Shenzhen New Industries Biomedical Engineering Co., Ltd.4Biosynex SA